Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX)
· seekingalpha.com
Celldex (CLDX) stays a Strong Buy as barzolvolimab hits Phase 3 CSU catalysts and CDX-622 advances; see 2026 data timeline and dilution risks—read now.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...